Cargando…

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas

The revised WHO classification newly defined the entities “High‐grade B‐cell lymphoma with MYC and BCL2, and/or BCL6 rearrangements (HGBL‐DH/TH)” and “HGBL, NOS.” Standard immunochemotherapy for diffuse large B‐cell lymphoma (DLBCL), R‐CHOP, is insufficient for HGBL patients, and there are currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Yuka, Momose, Shuji, Tabayashi, Takayuki, Sawada, Keisuke, Yamashita, Takahisa, Higashi, Morihiro, Sagawa, Morihiko, Tokuhira, Michihide, Rosenwald, Andreas, Kizaki, Masahiro, Tamaru, Jun‐ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004541/ https://www.ncbi.nlm.nih.gov/pubmed/31849147 http://dx.doi.org/10.1111/cas.14286

Ejemplares similares

CD24 is a surrogate for ‘immune‐cold’ phenotype in aggressive large B‐cell lymphoma
por: Higashi, Morihiro, et al.
Publicado: (2022)

Rapid deterioration of intravascular large B-cell lymphoma with mass formation in the trigeminal nerve and multiple organ infiltration: An autopsy case report
por: Tanaka, Yuka, et al.
Publicado: (2021)

The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders
por: Tokuhira, Michihide, et al.
Publicado: (2020)

Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma
por: Yamashita, Takahisa, et al.
Publicado: (2020)

TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
por: Sagawa, Morihiko, et al.
Publicado: (2015)

Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders
por: Tokuhira, Michihide, et al.
Publicado: (2019)

EBV-positive mucocutaneous ulcer arising in methotrexate-treated rheumatoid arthritis patients: a clinicopathological study of 12 cases with analysis of PD-L1 expression
por: Sawada, Keisuke, et al.
Publicado: (2023)

An infected thoracoabdominal aortic aneurysm mimicking the symptoms of urinary tract infection: A case report
por: Yamashita, Takahisa, et al.
Publicado: (2017)

Retroperitoneal Cystic Nodal Metastasis of Renal Cell Carcinoma
por: Yamashita, Takahisa, et al.
Publicado: (2018)

Better method for detection of CD30: Immunohistochemistry or flow cytometry?
por: Higashi, Morihiro, et al.
Publicado: (2021)

Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report
por: Tokuhira, Michihide, et al.
Publicado: (2009)

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
por: Liang, Muh-Lii, et al.
Publicado: (2020)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
por: Habler, Katharina, et al.
Publicado: (2022)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

Abemaciclib for breast cancer
Publicado: (2020)

Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting
por: Momose, Shuji, et al.
Publicado: (2019)

Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
por: Guney Eskiler, Gamze, et al.
Publicado: (2021)

Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway
por: SADAHIRA, KEN, et al.
Publicado: (2014)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

MODL-16. ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
por: Liang, Muh-Lii, et al.
Publicado: (2020)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
por: de Luna Aguilar, Alicia Milagros, et al.
Publicado: (2023)

Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment
por: Saito, Shuntaro, et al.
Publicado: (2018)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
por: Mitarai, Yuki, et al.
Publicado: (2022)

Clinicoradiological course of abemaciclib-induced pneumonitis with histology findings
por: Okayasu, Kaori, et al.
Publicado: (2023)

An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea
por: CAKCAK, İbrahim Ethem, et al.
Publicado: (2022)

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
por: Kosovec, Juliann E., et al.
Publicado: (2017)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8ku5bpjnt4eij5vuqnesbuqiv9